Related Experiment Video

Updated: Jun 3, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Management of the adverse effects of lenalidomide in multiple myeloma

Ana Pilar González Rodríguez1

  • 1Hematology Department, Hospital Central de Asturias, Oviedo, Asturias, Spain. anapilargonzalez@gmail.com

Advances in Therapy
|March 25, 2011
PubMed

Insights

New multiple myeloma treatments like lenalidomide improve outcomes. This review details lenalidomide

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Novel agents like thalidomide, bortezomib, and lenalidomide have advanced multiple myeloma treatment.
  • Improved treatment response and patient survival are key benefits.
  • Understanding drug toxicity is crucial for effective therapy and avoiding interruptions.

Purpose of the Study:

  • To review the primary hematological and non-hematological adverse effects of lenalidomide.
  • To discuss lenalidomide's common combinations in multiple myeloma therapy.
  • To provide recommendations for managing lenalidomide-associated adverse effects.

Main Methods:

  • Literature review of adverse effects associated with lenalidomide.
  • Analysis of common lenalidomide combination therapies for multiple myeloma.
  • Synthesis of management strategies for identified adverse events.

Main Results:

  • Identified key hematological toxicities (e.g., neutropenia, thrombocytopenia).
  • Highlighted common non-hematological adverse effects (e.g., fatigue, rash, venous thromboembolism).
  • Summarized management strategies including dose adjustments and supportive care.

Conclusions:

  • Effective management of lenalidomide's adverse effects is essential for maintaining treatment efficacy.
  • Proactive monitoring and intervention can mitigate toxicity and improve patient outcomes in multiple myeloma.
  • This review provides guidance for clinicians managing lenalidomide therapy.

Related Concept Videos

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Acute Kidney Injury VI: Nursing Management01:22

Acute Kidney Injury VI: Nursing Management

Acute Kidney Injury (AKI) results in an inability to maintain fluid, electrolyte, and acid-base balance. Effective nursing management is critical in improving patient outcomes and includes comprehensive patient assessment and targeted interventions.Comprehensive Patient AssessmentA detailed history collection is essential, focusing on any recent infections, nephrotoxic medication use, or chronic conditions such as hypertension and diabetes that may contribute to AKI. During the physical...
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.